Transdermal cannabinoid formulations

Patent metadata

Field	Value
Publication number	US-10028904-B2
Application number	US-201615195751-A
Country	US
Kind code	B2
Filing date	Jun 28, 2016
Priority date	Dec 4, 2014
Publication date	Jul 24, 2018
Grant date	Jul 24, 2018

Abstract

The present invention includes a transdermal composition which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The composition may comprise the following components: a surfactant-lecithin organogel; and a cannabinoid. The composition may also comprise an exogenous terpene. The cannabinoid is capable of diffusing from the composition into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia.

First claim

What is claimed is:

1. A transdermal composition comprising a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user, said composition comprising:
a) lecithin in an amount of between about 6% and about 20% w/w, high molecular weight acrylic acid polymers, PPG-2 myristyl ether propionate in an amount of between about 0.2% and about 5% w/w, at least one exogenous terpene or terpenoid in an amount of between about 0.05% and about 10% (w/w); water, in the amount of between 8% and 12% w/w, isopropyl myristate in an amount of between about 25% and 35% w/w, and oleic acid in an amount of between about 1% and 20% w/w;
with the proviso that the composition does not comprise a surfactant; and

b) at least one cannabinoid in an amount of between about 0.01% and about 5% w/w of the composition;
wherein at least 45% of the cannabinoid is delivered across the skin after 12 hours.

2. The composition of claim 1 , wherein the terpene or terpenoid comprises myrcene or menthol.

3. The composition of claim 1 , wherein the cannabinoid comprises THC.

4. The composition of claim 3 , wherein the THC is in an amount between about 0.1% and about 3%.

5. The composition of claim 1 , wherein the cannabinoid comprises THCa.

6. The composition of claim 5 , wherein the THCa is in an amount between about 0.1% and about 3%.

7. The composition of claim 1 , wherein the cannabinoid comprises CBD.

8. The composition of claim 7 , wherein the CBD is in an amount between about 0.1% and about 3%.

9. The composition of claim 1 , wherein the cannabinoid comprises CBDa.

10. The composition of claim 9 , wherein the CBDa is in an amount between 0.1% and about 3%.

11. The composition of claim 1 , wherein the cannabinoid comprises THCv, CBN, or CBC in an amount of between about 0.1% and about 3%.

12. A method for treating a patient suffering from a condition selected from the group consisting of pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia comprising administering the composition of claim 1 .

13. The composition of claim 1 , wherein the water is in the amount of 10% by weight of the organogel.

14. The composition of claim 1 , wherein at least 60% of the cannabinoid is delivered across the skin after 12 hours.

Assignees

• Mm Tech Holdings Llc
• Wisconsin Alumni Res Found

Inventors

• Smith Nicole
• Palmer Noel Erwin

Classifications

• A61K47/14

  Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title

• A61K9/0014 Primary

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61K47/24

  containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids · CPC title

• A61K31/01

  Hydrocarbons · CPC title

• A61K31/05

  Phenols {(cannabinoids A61K31/658)} · CPC title